trending Market Intelligence /marketintelligence/en/news-insights/trending/7xfVZBsgE81hgD_F0ALpCg2 content
Log in to other products

Login to Market Intelligence Platform


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

Thank you for your interest in S&P Global Market Intelligence! We noticed you've identified yourself as a student. Through existing partnerships with academic institutions around the globe, it's likely you already have access to our resources. Please contact your professors, library, or administrative staff to receive your student login.

At this time we are unable to offer free trials or product demonstrations directly to students. If you discover that our solutions are not available to you, we encourage you to advocate at your university for a best-in-class learning experience that will help you long after you've completed your degree. We apologize for any inconvenience this may cause.

In This List

Precision Therapeutics stockholders approve merger with Helomics

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry


IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help

Precision Therapeutics stockholders approve merger with Helomics

Precision Therapeutics Inc.'s stockholders approved an all-stock merger of personalized healthcare company Helomics Corp. at a special meeting.

The merger, which will increase Precision's stake in Helomics to 100%, is expected to become effective during the first part of April 2019.

Pittsburgh-based Helomics will become a unit of the healthcare products maker following the completion of the merger. Helomics develops, through research partnerships, personalized treatments and diagnostic technologies to help improve patient care.

Under the terms of the agreement, Precision will issue 4 million common shares and 3.5 million series D convertible preferred shares to holders of Helomics capital stock. This issuance is in addition to the 1.1 million Precision common shares previously issued to Helomics as consideration for its prior acquisition of a 20% ownership interest in Helomics.

Each series D preferred share is convertible into 1 common share of Precision starting one year after issuance.

Precision's shareholders also approved the issuance of common shares and warrants to the holders of Helomics notes and warrants in an exchange offer.

The holders of $7.3 million of Helomics' notes — representing about 96% of Helomics' notes — have accepted the terms of the exchange offer, which was one of the conditions for the consummation of the merger.

Under the exchange offer, Precision will issue common shares and warrants to buy common shares based on the exchange of $8.6 million in outstanding promissory notes and the associated Helomics warrants.

Precision will issue about 8.6 million additional common shares, about 14.2 million warrants to buy its common shares at an exercise price of $1.00 per share and 600,000 warrants to buy its common shares at an exercise price of 1 cent per share.

Eagan, Minn.-based Precision Therapeutics provides personalized medicine solutions for the pharmaceutical, diagnostic and biotech industries.